Overview

Study of NGM313 in Obese Participants

Status:
Completed
Trial end date:
2018-07-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants
Phase:
Phase 1
Details
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Treatments:
Pioglitazone